United-Guardian (UG) AI Stock Analysis

• Market Cap: $37.44M
• Dividend Yield: 8.59%
• Average Volume (3M): 9.93K
• Price to Earnings (P/E): 13.0
• Beta (1Y): 0.27
• Revenue Growth: 11.91%
• EPS Growth: 25.93%
• Country: US
• Employees: 24
• Sector: Consumer Cyclical
• Sector Strength: 76
• Industry: Household & Personal Products
• EPS (TTM): 0.12
• Shares Outstanding: 4,594,319
• 10 Day Avg. Volume: 3,996
• 30 Day Avg. Volume: 9,927
• PEG Ratio: -1.93
• Price to Book (P/B): 3.48
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 13.62
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 71 Outperform
• Price Target: ―

United-Guardian's overall stock score reflects its strong financial performance, driven by profitability and cash flow management, despite some concerns over revenue growth and equity stability. The technical analysis indicates a bearish trend, but the stock's attractive valuation, with a low P/E ratio and high dividend yield, offers potential for income and appreciation. The ongoing commitment to dividends is an added strength, reinforcing the company's dedication to shareholder value.

United-Guardian Business Overview & Revenue Model

Company Description

United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally. The company offers cosmetic ingredients, including LUBRAJEL line of water-based moisturizing and lubricating gel formulations; LUBRAJEL NATURAL consisting of natural ingredients for cosmetic use; LUBRAJEL MARINE; LUBRASIL II SB, a special formulation of LUBRAJEL in which silicone oil is incorporated into a LUBRAJEL base; LUBRAJEL II XD; B-122, a powdered lubricant that is used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; KLENSOFT, a surfactant, which is used in shampoos, shower gels, makeup removers, and other cosmetic formulations; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, cleansers, and other cosmetics. Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL LC and LUBRAJEL FA that are LUBRAJEL formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. The company's pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial product to treat infections in the urinary bladder, and localized infections in the peritoneum, as well as eye, ear, nose and throat, and sinuses. Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. The company also conducts research and development primarily related to the development of cosmetic ingredients. It markets its products through marketing partners, distributors, and wholesalers. The company was founded in 1942 and is based in Hauppauge, New York.

How the Company Makes Money

United-Guardian makes money through the manufacturing and sale of its proprietary products across various sectors. The company's revenue model is based on direct sales and distribution agreements with other companies, which include licensing agreements and partnerships that allow for broader market reach. Key revenue streams include the sale of personal care products like skincare and haircare formulations, pharmaceutical products including medical lubricants used in hospitals and clinics, and specialty industrial products utilized in manufacturing processes. Significant partnerships with major distribution companies also play a crucial role in ensuring the widespread availability of United-Guardian's products, thereby contributing to its earnings.

United-Guardian Financial Statement Overview

Summary

United-Guardian demonstrates robust profitability and cash flow management, offset by some volatility in revenue growth and balance sheet stability. The company's lack of debt is a strength, but the recent absence of equity raises questions about its financial strategy. Overall, the company is financially sound but needs to focus on stabilizing revenue growth and strengthening its equity position.

Income Statement

United-Guardian has shown a consistent gross profit margin and strong net profit margins over the years. The EBIT and EBITDA margins are robust, indicating efficient operations. However, revenue growth has been inconsistent, which is a concern for long-term sustainability.

Balance Sheet

The company's balance sheet is strong with no debt, leading to a healthy debt-to-equity ratio. However, the lack of equity in the latest period is a notable concern. The equity ratio has fluctuated, indicating some instability in financial structure.

Cash Flow

Cash flow management is a strong point for United-Guardian, with healthy operating cash flows and positive free cash flows. The company has shown an ability to maintain free cash flow growth, although fluctuations in investing cash flow may pose future challenges.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
12.18M	10.89M	12.70M	13.93M	10.99M
	Gross Profit
6.46M	5.41M	6.70M	8.18M	6.11M
	EBIT
3.65M	2.86M	4.04M	5.67M	3.64M
	EBITDA
3.65M	2.97M	4.17M	5.81M	3.80M
	Net Income Common Stockholders
3.25M	2.58M	2.57M	4.66M	3.30M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
9.40M	9.09M	6.48M	8.17M	8.18M
	Total Assets
13.80M	12.92M	10.64M	12.24M	11.92M
	Total Debt
0.00	0.00	0.00	0.00	0.00
	Net Debt
-1.88M	-8.24M	-830.45K	-531.21K	-591.44K
	Total Liabilities
1.91M	1.53M	1.37M	2.42M	1.57M
	Stockholders Equity
11.88M	11.39M	9.27M	9.82M	10.35M
Cash Flow		Free Cash Flow
3.47M	2.98M	2.45M	5.20M	3.55M
	Operating Cash Flow
3.47M	3.14M	2.53M	5.31M	3.59M
	Investing Cash Flow
-7.08M	4.73M	897.56K	-183.47K	-468.68K
	Financing Cash Flow
-2.76M	-459.39K	-3.12M	-5.19M	-3.58M

United-Guardian Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UG, the sentiment is Negative. The current price of 8.14 is below the 20-day moving average (MA) of 8.15, below the 50-day MA of 8.57, and below the 200-day MA of 10.71, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 45.10 is Neutral, neither overbought nor oversold. The STOCH value of 23.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UG.

United-Guardian Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UG	71 Outperform	$37.44M	12.97	26.24%	8.59%	11.91%	25.93%
CRWS	67 Neutral	$33.16M	13.54	4.76%	9.78%	-0.07%	-49.06%
RGS	65 Neutral	$54.35M	0.59	548.07%	―	-4.88%	―
Sector *	62 Neutral	$6.84B	11.22	2.83%	3.93%	2.65%	-21.93%
SYPR	55 Neutral	$44.35M	―	-1.87%	―	-3.83%	89.89%
INTG		$25.85M	―		―	―	―
NHTC	50 Neutral	$53.39M	105.15	1.44%	17.28%	-0.62%	1.15%

United-Guardian Corporate Events

United-Guardian Announces 30th Consecutive Year of Dividends

On January 30, 2025, United-Guardian announced a cash dividend of $0.35 per share, payable on February 18, 2025, marking the 30th consecutive year of dividends. The dividend reflects the company’s commitment to shareholder returns, consistent with the previous dividend in July 2024, and underscores its strategy to monitor earnings and distribute dividends when beneficial.